WEBULL
WebtradeDownload

Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?

Simply Wall St · 3d ago

Travere Therapeutics (TVTX) drew fresh attention after the USPTO issued a Notice of Allowance for a FILSPARI patent in focal segmental glomerulosclerosis, extending anticipated U.S. method of use protection into October 2037.

Travere Therapeutics has seen mixed short term momentum, with the share price down 9.49% over the past 30 days but up 5.39% over 90 days. The year to date share price return of 51.80% and a very large three year total shareholder return of about 7x point to strong longer term sentiment. This latest patent win and the orderly CEO transition may be helping to frame that sentiment as investors reassess both growth potential and risk around FILSPARI and the wider rare disease portfolio.

Compare Travere Therapeutics with other rare disease and biotech players showing strong momentum by reviewing the hand picked 17 high quality undiscovered gems in this space.

Bulls point to Travere Therapeutics’ extended FILSPARI patent life and rare disease focus. Bears highlight ongoing losses and execution risk. Which side does the current valuation math come closer to supporting?

Most Popular Narrative: 19% Undervalued

Travere Therapeutics last closed at $59.99, while the most followed narrative pegs fair value at about $74.14, framing the current price as a discount built on FILSPARI execution and rare kidney focus.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market. If approved, this will create a new, high-margin revenue stream and significantly expand the company's addressable market. (Revenue growth, gross margins)

See why 22 investors see Travere Therapeutics as 19% undervalued.

Result: Fair Value of $74.14 (UNDERVALUED)

Still, the bullish Travere Therapeutics story leans heavily on FILSPARI. Any setback in FSGS approval or competition that arrives faster than expected could quickly weaken that thesis.

Find out about the key risks to this Travere Therapeutics narrative.

Another View on Travere Therapeutics Valuation

On the other side of that 19% undervalued story sits a much tougher read from simple sales multiples. Travere Therapeutics trades on a P/S of 9.6x, compared with a fair ratio of 7.9x and about 7.3x for peers. That richer tag suggests less margin for error if the FILSPARI thesis hits any bumps.

See what the numbers say about this price in more detail by reviewing See what the numbers say about this price — find out in our valuation breakdown..

NasdaqGM:TVTX P/S Ratio as at Sep 2026
NasdaqGM:TVTX P/S Ratio as at Sep 2026

Next Steps

Sentiment on Travere Therapeutics is divided, so it helps to see the raw data and decide where you stand before the crowd does. To understand why some investors are focusing on potential upside, review the 4 key rewards.

Looking For More Investment Ideas Beyond Travere Therapeutics?

If Travere Therapeutics has you rethinking what qualifies as opportunity, use that same curiosity to hunt for other setups where price and quality still line up.

Scan fresh possibilities and pressure test your next moves with these focused stock ideas drawn from the Simply Wall Street screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.